That very day, Jin Yihong brought Lou Musaang, Jia Jun, and Deng Feifei to meet with Wu Ting for a discussion.
They proposed a plan to counter Pfizer: go all-in on promoting Wu Ting's new drug, Fengmu Tiada, to restore market confidence and temporarily stabilize the Jin Pharmaceutical Group's stock price.
As the second phase of investment in Wu's Pharmaceutical Company, the usage rights for some of the production lines, factories, and laboratories originally slated for the Yangzheng Xiujie Pill were transferred to Wu's Pharmaceutical Company.
To bolster Wu Ting's research team, Jia Jun led a team to transfer to Wu's Pharmaceutical Company, where they would assist Wu Ting and Deng Feifei in the research for the new drug, Fengmu Tiada.
Wu Ting, in turn, secured a high-risk, high-reward condition from this collaboration: he could swap equity in Wu's Pharmaceutical Company for equity in the Jin Pharmaceutical Group.
